Incannex Healthcare EBITDA 2023-2024 | IXHL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Incannex Healthcare ebitda from 2023 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Incannex Healthcare ebitda from 2023 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$79.9B
Zoetis (ZTS)	$70.1B
Daiichi Sankyo, - (DSNKY)	$43.9B
Takeda Pharmaceutical (TAK)	$43.7B
Sandoz Group AG (SDZNY)	$20.6B
Merck (MKKGY)	$18.3B
Astellas Pharma (ALPMY)	$17.4B
United Therapeutics (UTHR)	$17B
Summit Therapeutics (SMMT)	$15.9B
Shionogi (SGIOY)	$12.3B
Neurocrine Biosciences (NBIX)	$11.4B
Corcept Therapeutics (CORT)	$7.7B
Madrigal Pharmaceuticals (MDGL)	$7.5B
Orion OYJ (ORINY)	$7.4B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Stevanato Group S.p.A (STVN)	$6.2B
Grifols, S.A (GRFS)	$5.1B
Ionis Pharmaceuticals (IONS)	$5B
Ono Pharmaceutical (OPHLF)	$4.7B
Recursion Pharmaceuticals (RXRX)	$4.2B
Crinetics Pharmaceuticals (CRNX)	$3.4B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.4B
Hypermarcas (HYPMY)	$2.2B
Centessa Pharmaceuticals (CNTA)	$2.1B
Soleno Therapeutics (SLNO)	$2B
BioCryst Pharmaceuticals (BCRX)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.8B
Evotec AG (EVO)	$1.6B
Ardelyx (ARDX)	$1.5B